CD19-CAR modified T cell therapy is a powerful and potentially curative option for patients with relapsed/refractory CD19-expressing B-cell malignancies. I am part of a team dedicated to making clinical-grade autologous CD19 CAR-T Cell therapy products for patients from across Canada that are enrolled on our CLIC-01 (Canadian-led Immunotherapies in Cancer) trial. I am also involved in the Point-of-Care (POC) project, which is working to build a Canadian CAR-T cell manufacturing network that will help bring this new therapy to Canadian patients in an equitable and sustainable manner.
B.Sc. Biochemistry & Microbiology, University of Victoria, 2006
M.Sc. Biochemistry, University of Victoria, 2010